Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Phase 4CompletedNCT01903070

Profil Institut für Stoffwechselforschung GmbH99 enrolled

Overview

This is a bi-centric, prospective, open study comparing the effects of linagliptin on active GLP-1 concentrations in subjects with renal impairment compared to subjects with normal renal function.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

LinagliptinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have Type 2 diabetes mellitus based on the disease diagnostic criteria (WHO) classification Exclusion Criteria: * Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis.

Locations (1)

Profil Institut für Stoffwechselforschung GmbH

Neuss, North Rhine-Westphalia, Germany

Outcomes

Primary Outcomes

ΔAUCGLP-1-OGTT(0-240)

ΔAUCGLP-1-OGTT(0-240) Change in active GLP-1 concentrations after oral glucose ingestion after linagliptin Treatment compared between Groups.

Time frame: Glucose tolerance test following 7 days of therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.